Roger Perlmutter’s latest ‘retirement’ gig opens a door to the bustling China biotech scene
Roger Perlmutter will be doing some globetrotting for the next chapter in his long-running biopharma bio — though the actual travel part may be on hold through the pandemic.
Earlier in the week, we learned that Perlmutter, who stepped down from his post as head of R&D at the start of this year, has signed on as a science adviser to the Shanghai-based CBC group, a prominent investment group that’s been fostering some of the big new biotech startups in Asia.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.